vs
Apellis Pharmaceuticals, Inc.（APLS）与DoubleVerify Holdings, Inc.（DV）财务数据对比。点击上方公司名可切换其他公司
DoubleVerify Holdings, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$205.6M vs $199.9M），DoubleVerify Holdings, Inc.净利率更高（14.3% vs -29.5%，领先43.8%），DoubleVerify Holdings, Inc.同比增速更快（7.9% vs -5.9%），DoubleVerify Holdings, Inc.自由现金流更多（$62.1M vs $-14.3M），过去两年DoubleVerify Holdings, Inc.的营收复合增速更高（20.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
DoubleVerify Holdings是一家专注于媒体测量、分析及验证的技术服务商，核心业务为品牌安全、广告可见度、反广告欺诈等，帮助广告主、发布商及平台方优化数字广告投放效果，保障营销投入的ROI，业务覆盖全球多个市场。
APLS vs DV — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $205.6M |
| 净利润 | $-59.0M | $29.3M |
| 毛利率 | — | 82.5% |
| 营业利润率 | -25.6% | 18.4% |
| 净利率 | -29.5% | 14.3% |
| 营收同比 | -5.9% | 7.9% |
| 净利润同比 | -62.2% | 25.3% |
| 每股收益（稀释后） | $-0.40 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $205.6M | ||
| Q3 25 | $458.6M | $188.6M | ||
| Q2 25 | $178.5M | $189.0M | ||
| Q1 25 | $166.8M | $165.1M | ||
| Q4 24 | $212.5M | $190.6M | ||
| Q3 24 | $196.8M | $169.6M | ||
| Q2 24 | $199.7M | $155.9M | ||
| Q1 24 | $172.3M | $140.8M |
| Q4 25 | $-59.0M | $29.3M | ||
| Q3 25 | $215.7M | $10.2M | ||
| Q2 25 | $-42.2M | $8.8M | ||
| Q1 25 | $-92.2M | $2.4M | ||
| Q4 24 | $-36.4M | $23.4M | ||
| Q3 24 | $-57.4M | $18.2M | ||
| Q2 24 | $-37.7M | $7.5M | ||
| Q1 24 | $-66.4M | $7.2M |
| Q4 25 | — | 82.5% | ||
| Q3 25 | — | 82.3% | ||
| Q2 25 | — | 82.5% | ||
| Q1 25 | — | 81.2% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | 82.6% | ||
| Q2 24 | — | 83.3% | ||
| Q1 24 | — | 81.1% |
| Q4 25 | -25.6% | 18.4% | ||
| Q3 25 | 48.7% | 11.2% | ||
| Q2 25 | -18.6% | 7.2% | ||
| Q1 25 | -50.0% | 4.1% | ||
| Q4 24 | -12.3% | 20.3% | ||
| Q3 24 | -24.0% | 15.2% | ||
| Q2 24 | -14.7% | 7.1% | ||
| Q1 24 | -36.0% | 4.9% |
| Q4 25 | -29.5% | 14.3% | ||
| Q3 25 | 47.0% | 5.4% | ||
| Q2 25 | -23.6% | 4.6% | ||
| Q1 25 | -55.3% | 1.4% | ||
| Q4 24 | -17.1% | 12.3% | ||
| Q3 24 | -29.2% | 10.7% | ||
| Q2 24 | -18.9% | 4.8% | ||
| Q1 24 | -38.5% | 5.1% |
| Q4 25 | $-0.40 | $0.18 | ||
| Q3 25 | $1.67 | $0.06 | ||
| Q2 25 | $-0.33 | $0.05 | ||
| Q1 25 | $-0.74 | $0.01 | ||
| Q4 24 | $-0.30 | $0.14 | ||
| Q3 24 | $-0.46 | $0.10 | ||
| Q2 24 | $-0.30 | $0.04 | ||
| Q1 24 | $-0.54 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $259.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.1B |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $259.0M | ||
| Q3 25 | $479.2M | $200.7M | ||
| Q2 25 | $370.0M | $216.8M | ||
| Q1 25 | $358.4M | $174.3M | ||
| Q4 24 | $411.3M | $310.6M | ||
| Q3 24 | $396.9M | $362.6M | ||
| Q2 24 | $360.1M | $338.8M | ||
| Q1 24 | $325.9M | $334.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $1.1B | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $1.0B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.1B | ||
| Q1 24 | $266.7M | $1.1B |
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.3B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $1.3B | ||
| Q3 24 | $901.9M | $1.3B | ||
| Q2 24 | $904.5M | $1.3B | ||
| Q1 24 | $831.9M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $72.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $62.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 30.2% |
| 资本支出强度资本支出/营收 | 0.1% | 5.1% |
| 现金转化率经营现金流/净利润 | — | 2.48× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $172.7M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $72.7M | ||
| Q3 25 | $108.5M | $51.2M | ||
| Q2 25 | $4.4M | $49.6M | ||
| Q1 25 | $-53.4M | $37.7M | ||
| Q4 24 | $19.4M | $37.4M | ||
| Q3 24 | $34.1M | $54.6M | ||
| Q2 24 | $-8.3M | $35.9M | ||
| Q1 24 | $-133.0M | $31.8M |
| Q4 25 | $-14.3M | $62.1M | ||
| Q3 25 | $108.3M | $39.0M | ||
| Q2 25 | $4.4M | $40.1M | ||
| Q1 25 | $-53.4M | $31.4M | ||
| Q4 24 | $19.3M | $30.0M | ||
| Q3 24 | — | $48.4M | ||
| Q2 24 | $-8.4M | $28.7M | ||
| Q1 24 | $-133.3M | $25.4M |
| Q4 25 | -7.1% | 30.2% | ||
| Q3 25 | 23.6% | 20.7% | ||
| Q2 25 | 2.5% | 21.2% | ||
| Q1 25 | -32.0% | 19.0% | ||
| Q4 24 | 9.1% | 15.8% | ||
| Q3 24 | — | 28.5% | ||
| Q2 24 | -4.2% | 18.4% | ||
| Q1 24 | -77.3% | 18.0% |
| Q4 25 | 0.1% | 5.1% | ||
| Q3 25 | 0.0% | 6.4% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | 0.0% | 3.8% | ||
| Q4 24 | 0.0% | 3.9% | ||
| Q3 24 | 0.0% | 3.7% | ||
| Q2 24 | 0.0% | 4.6% | ||
| Q1 24 | 0.2% | 4.5% |
| Q4 25 | — | 2.48× | ||
| Q3 25 | 0.50× | 5.02× | ||
| Q2 25 | — | 5.66× | ||
| Q1 25 | — | 15.95× | ||
| Q4 24 | — | 1.60× | ||
| Q3 24 | — | 3.00× | ||
| Q2 24 | — | 4.80× | ||
| Q1 24 | — | 4.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
DV
| Activation | $116.5M | 57% |
| Measurement | $69.6M | 34% |
| Supply Side | $19.5M | 9% |
